Search Within

Guilherme Harada

Formats
  1. Journal Article (14)
  2. Meeting Abstract (10)
  3. Review (3)
  4. Editorial (1)
Groups
  1. GME, Medicine (28)
  2. Graduate Medical Education (28)
  3. Department of Medicine (26)
  4. Solid Tumor Oncology Division (26)
  5. Thoracic Oncology (25)
  6. Hematology-Oncology Fellows (11)

More Groups

People
  1. Alexander Drilon (25)
  2. Christina Falcon (8)
  3. Clare Wilhelm (7)
  4. Dazhi Liu (6)
  5. Soo Ryum Yang (6)
  6. Monica Chen (5)

More People

Years
  1. 2025 (3)
  2. 2024 (7)
  3. 2023 (8)
  4. 2022 (9)
  5. 2021 (1)
Publications
  1. Journal of Clinical Oncology (5)
  2. Journal of Thoracic Oncology (5)
  3. Clinical Cancer Research (3)
  4. JCO Precision Oncology (2)
  5. Annals of Oncology (1)
  6. Annual Review of Cancer Biology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (6)
  3. Elsevier Inc. (6)
  4. Nature Publishing Group (2)
  5. Oxford University Press (2)
  6. Annual Reviews (1)

More Publishers

Results (28)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Journal Article

    Calvo, E.; Sessa, C.; Harada, G.; de Miguel, M.; Kahatt, C.; Luepke-Estefan, X. E.; Siguero, M.; Fernandez-Teruel, C.; Cullell-Young, M.; Stathis, A.; more...
    Investigational New Drugs (2022)

    Fulltext@MSK | Save
  • EGFR tyrosine kinase inhibitors and combination strategies in first-line treatment of advanced NSCLC: A network meta-analysis
    Meeting Abstract

    de Castro, G.; Stock, G. T.; Harada, G.; Pereira, A. A. L.; Sadeghirad, B.
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Brief Report: Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy
    Journal Article

    Kalchiem-Dekel, O.; Falcon, C. J.; Bestvina, C. M.; Liu, D.; Kaplanis, L. A.; Wilhelm, C.; Eichholz, J.; Harada, G.; Wirth, L. J.; Digumarthy, S. R.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • An ascendant challenge: Central nervous system metastases in ALK+ lung cancers
    Editorial

    Murciano-Goroff, Y. R.; Harada, G.; Drilon, A.
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • ALK inhibitors in patients with ALK fusion-positive GI cancers: An international data set and a molecular case series
    Journal Article

    Ambrosini, M.; Del Re, M.; Manca, P.; Hendifar, A.; Drilon, A.; Harada, G.; Ree, A. H.; Klempner, S.; Maelandsmo, G. M.; Flatmark, K.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults
    Journal Article

    Harada, G.; Drilon, A.
    Cancer Genetics (2022)

    Fulltext@MSK | Save
  • NTRK fusions in lung cancer: From biology to therapy
    Review

    Harada, G.; Santini, F. C.; Wilhelm, C.; Drilon, A.
    Lung Cancer (2021)

    Fulltext@MSK | Save